Expiration date: 02/2025

Indications

Early stages of breast cancer, whose cells have hormone receptors, in postmenopausal women as adjuvant therapy.

Contraindications

Hypersensitivity to Metrology or any component of the drug; endocrine status, characteristic of reproductive age; pregnancy; lactation; children's age (the efficacy and safety for children has not been established).

Description

The active ingredient in Loreto (letrozole) has anti-estrogenic action, selectively inhibits aromatase (the enzyme of the synthesis of estrogen) by a highly specific competitive binding subunit of this enzyme - heme of cytochrome P450. Blocks the synthesis of estrogens in both peripheral and tumor tissues. In postmenopausal women, estrogens are formed mainly with the participation of the enzyme aromatase, which converts androgens synthesized in the adrenal glands (primarily Androstenedione and testosterone) into estrone and estradiol.

Form release

Tablets.

Composition

Letrozole (Letrozole). Antitumor agent-estrogen synthesis inhibitor.